Rachel is a neurobiologist by training and has held various roles in business development across non-profit and the biotech industry. Prior to joining Calico, Rachel was responsible for portfolio strategy at Ovid Therapeutics working across business development, finance and the project teams. In this role, Rachel led search and evaluation activities, supported the development of a partnership with Takeda Pharmaceuticals to bring a Phase 2 CNS compound into the pipeline and was a key member of the team that led the initial public offering (IPO).
Prior to Ovid, Rachel held positions in both non-profit at the Alzheimer’s Drug Discovery Foundation (ADDF) and on Wall Street. She trained in cell and molecular biology, and completed postdoctoral research at Icahn School of Medicine at Mount Sinai on the neurobiology of Alzheimer’s disease.
- Ph.D. in Cell and Molecular Biology, University of Sheffield
- B.Sc. (Hons) in Biomedical Sciences, Sheffield Hallam University